References
- Bahmer FA. Topical levocabastine – an effective alternative to oral antihistamines in seasonal allergic rhino-conjunctivitis. Clin Exp Allergy 1995;25:220–7
- Chand N. Antagonism of histamine and leukotrienes by azelastine in isolated guinea pig ileum. Agents Actions 1986;19(3/4):164–8
- Achterrath-Tuckerman U, Weischer CH, Szelenyi I. Azelastine, a new antiallergic/antiasthmatic agent, inhibits PAF-acether-induced platelet aggregation, paw oedema and bronchoconstriction. Pharmacology 1988;36:265–71
- Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Bagnasco M, Grögen J, Mela GS, Canonica GW. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996;98: 1088–96
- McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1989;38(5):778–800
- Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye drops in seasonal allergic conjunctivitis or rhino-conjunctivitis. Allergy 1998;53:857–62
- Lenhard G, Mivsek-Music E, Perrin-Fayolle M, Obtulowicz K, Secchi A. Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhino-conjunctivitis. Curr Med Res Opin 1997;14:21–8
- Giede C, Metzenauer P, Petzold, U. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000;16:153–63
- Sabbah A, Marzetto, M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhino-conjunctivitis in young children. Curr Med Res Opin 1998;14:161–70
- Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997;27:182–91
- Abelson MB, George MG, Schaefer K, Smith LM. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol 1994;3: 458–64
- Allansmith MR, Ross RN. Ocular allergy. Rev Clin Allergy 1988;18:1–13
- Leino M, Ennevaara K, Latvala A-L, Nordgren P, Posti A-M, Suves R, Takalo E. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1992;22: 929–32
- Davies BH, Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993;48:519–24
- Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Beclomethasone diproprionate: II: Allergic rhinitis and other conditions. Drugs 1975;10:211–17
- Howarth PH. A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management. Mediators Inflamm 1995;4(Suppl):526–30
- Sorkin EM, Ward A. Ocular sodium cromoglycate, an overview of its therapeutic efficacy in allergic eye disease. Drugs 1986;31:131–48
- Blumenthal M, Casale T, Dockhorn R, Jarmoszuk I, Kaiser H, Smith R, Zeitz HJ. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1992;113:56–63